Does Sandoz (dextroamphetamine) come in a 10 mg formulation for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and narcolepsy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 29, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Dextroamphetamine 10 mg Formulation Availability

Yes, dextroamphetamine is available in a 10 mg formulation, specifically as Dexedrine Spansule (sustained-release capsule), with the starting dose being 10 mg once daily in the morning. 1

Available Formulations and Dosing

Immediate-Release Formulation

  • Dextroamphetamine immediate-release tablets typically start at 5 mg, given once or twice daily 2
  • For narcolepsy in patients 12 years and older, the starting dose is 10 mg daily, with increases of 10 mg at weekly intervals until optimal response is achieved 1
  • The immediate-release form is dosed at 4-6 hour intervals throughout the day 1

Sustained-Release Formulation (Spansule)

  • Dexedrine Spansule starts at 10 mg once daily in the morning 2
  • This formulation can be increased by 5 mg increments as needed 2
  • The Spansule is commonly combined with immediate-release dextroamphetamine for flexible dosing and breakthrough symptom coverage 3

Clinical Context for 10 mg Dosing

ADHD Treatment

  • For ADHD in children 6 years and older, the starting dose is 5 mg once or twice daily, with weekly increases of 5 mg until optimal response 1
  • The 10 mg dose would represent a titrated dose after initial treatment establishment 2

Narcolepsy Treatment

  • For narcolepsy in patients 12 years and older, 10 mg daily is the recommended starting dose 1
  • Total daily doses for narcolepsy typically range from 5-60 mg depending on individual response 1
  • Dextroamphetamine is conditionally recommended as a second-line agent for narcolepsy, reserved for cases where first-line treatments (modafinil, solriamfetol, sodium oxybate, pitolisant) are ineffective or contraindicated 3, 4

Important Prescribing Considerations

  • Dextroamphetamine is a DEA Schedule II controlled substance with high potential for abuse and dependence 3, 4
  • Late evening doses should be avoided due to insomnia risk 1
  • Common adverse effects include appetite suppression, weight loss, irritability, and cardiovascular effects 3, 4
  • Regular monitoring for signs of tolerance, abuse behaviors, and cardiovascular effects is essential 3, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Narcolepsy Management with Dextroamphetamine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Narcolepsy Treatment with Dextroamphetamine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.